centerforbiosimilars1h
Bevacizumab Biosimilars Show Similar Efficacy, Safety in NSCLC
Patients with non-small cell lung cancer (NSCLC) taking bevacizumab biosimilars demonstrated equivalent therapeutic efficacy ...
centerforbiosimilars1d
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements
The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their ...
centerforbiosimilars2d
3 Ustekinumab Biosimilars Launch on US Market
Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara ...
centerforbiosimilars3d
Josh Canavan, PharmD
Cetuximab Biosimilar Receives NMPA Approval for RAS/BRAF Wild-Type CRC ...
centerforbiosimilars3d
Dinakaran Balasubramanian
Cetuximab Biosimilar Receives NMPA Approval for RAS/BRAF Wild-Type CRC ...
centerforbiosimilars4d
Will the FTC Be More PBM-Friendly Under A Second Trump Administration?
On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy ...
centerforbiosimilars4d
Derek Burns, PharmD, MBA, BCPS, BCSCP
Cetuximab Biosimilar Receives NMPA Approval for RAS/BRAF Wild-Type CRC ...
centerforbiosimilars4d
Nancy J. Globus, PharmD
Cetuximab Biosimilar Receives NMPA Approval for RAS/BRAF Wild-Type CRC ...
centerforbiosimilars4d
Lana Pine
Cetuximab Biosimilar Receives NMPA Approval for RAS/BRAF Wild-Type CRC ...
centerforbiosimilars4d
James D. Chambers, PhD, MPharm, MSc
Cetuximab Biosimilar Receives NMPA Approval for RAS/BRAF Wild-Type CRC ...
centerforbiosimilars5d
Travis Brewer
Cetuximab Biosimilar Receives NMPA Approval for RAS/BRAF Wild-Type CRC ...
centerforbiosimilars5d
St John Skilton, PhD
Cetuximab Biosimilar Receives NMPA Approval for RAS/BRAF Wild-Type CRC ...